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Abstract

Author Manuscript

Apurinic/apyrimidinic endonuclease 1 (APE1) is an essential protein crucial for repair of oxidized
DNA damage not only in genomic DNA but also in mitochondrial DNA. Parkin, a tumor
suppressor and Parkinson’s disease (PD) associated gene, is an E3 ubiquitin ligase crucial for
mitophagy. While DNA damage is known to induce mitochondrial stress, Parkin’s role in
regulating DNA repair proteins has not been elucidated. In this study, we examined the possibility
of Parkin-dependent ubiquitination of APE1. Ectopically expressed APE1 was degraded by Parkin
and PINK1 via polyubiquitination in mouse embryonic fibroblast cells. PD-causing mutations in
Parkin and PINK1 abrogated APE1 ubiquitination. Interaction of APE1 with Parkin was observed
by co-immunoprecipitation, proximity ligation assay, and co-localization in the cytoplasm. Nterminal deletion of 41 amino acid residues in APE1 significantly reduced the Parkin-dependent
APE1 degradation. These results suggested that Parkin directly ubiquitinated N-terminal Lys
residues in APE1 in the cytoplasm. Modulation of Parkin and PINK1 activities under
mitochondrial or oxidative stress caused moderate but statistically significant decrease of
endogenous APE1 in human cell lines including SH-SY5Y, HEK293, and A549 cells. Analyses of
glioblastoma tissues showed an inverse relation between the expression levels of APE1 and Parkin.
These results suggest that degradation of endogenous APE1 by Parkin occur when cells are
stressed to activate Parkin, and imply a role of Parkin in maintaining the quality of APE1, and loss
of Parkin may contribute to elevated APE1 levels in glioblastoma.
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Introduction
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Oxidatively damaged DNA is primarily repaired by DNA base excision repair. In the
mammalian DNA base excision repair pathway, apurinic/apyrimidinic (AP) endonuclease
(APE1) incises DNA upstream of AP sites to generate single-strand breaks (SSBs) with 3′OH termini for subsequent DNA repair synthesis reactions [1]. APE1 is shown to be
essential during mouse embryonic development and is the only active AP-endonuclease in
mammals. Studies also demonstrated that APE1 was indispensable for cultured cells [2,3],
although recent studies demonstrated that cells derived from a B lymphocyte line could
survive without APE1 [4,5]. APE1 also functions as a gene expression regulator by
redoxically activating oncogenic and pro-survival transcription factors such as AP-1 and NFκB, and is also involved in gene regulation necessary for calcium homeostasis [6,7].
Therefore, APE1 is a pro-survival multifunctional protein. Drug and radiation resistance of
tumor tissues have been linked to increased APE1 expression [8–12].
APE1 is post-translationally modified by phosphorylation, acetylation, and ubiquitination
[13–19]. APE1 was found to be ubiquitinated by MDM2 [20,21], the major p53 regulator
[22,23]. However, APE1 ubiquitination was later observed in mouse embryonic fibroblast
defective of MDM2 [20], implying existence of backup activities for APE1 ubiquitination
other than MDM2. Meisenberg et al. identified UBR3 as another E3 ubiquitin ligase for
APE1 [24].

Author Manuscript
Author Manuscript

Properly maintained mitochondrial membrane potential is critical to meet cellular energy
demands through oxidative phosphorylation. Electron leaks from the respiratory chain
complexes result in the generation of superoxide (O2−). The mitochondrial superoxide
dismutase is extremely efficient in scavenging O2− [25], and thus cells at normal growth
conditions maintain the oxidative stress at a manageable level. This status quo may be
broken by exogenous reagents, genotoxic stresses, and gene mutations that impair
mitochondria [26–28]. Damaged mitochondria elevate intracellular reactive oxygen species
(ROS), and result in further impairment of mitochondria [29]. To avoid this vicious cycle, a
salvaging process named mitophagy is initiated to break down damaged mitochondria and
generate new mitochondria [30]. It is becoming apparent that mitophagy is modulated by
DNA damage responses. Recent studies found that activation of poly(ADP-ribose)
polymerase 1 (PARP1) by DNA strand breaks plays a pivotal role in the energy metabolism
[31,32]. In the process of DNA repair, oxidative DNA damage are converted to DNA strand
breaks as intermediate lesions [33]. The suppression of mitophagy by the activated PARP
may be a self-feedback system during the repair of endogenous DNA damage. However,
understanding the interplay among factors for mitophagy and DNA repair proteins is far
from complete.
During mitophagy, proteins in damaged mitochondria are degraded via polyubiquitination,
which is mainly carried out by Parkin, a RING domain-containing E3 ubiquitin ligase [34].
PINK1 (PTEN-induced-kinase 1) is a critical activator of Parkin [30,34]. PINK1
phosphorylates ubiquitin and Parkin [35–38], and recruits Parkin from cytoplasm to
mitochondrial surfaces to facilitate ubiquitination of its target proteins such as mitofusin 2
(Mfn2), Miro, and VDAC1 [39,40]. Mutations in the Parkin and the PINK1 genes cause
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mitochondrial degeneration and are associated with PD [30] and glioblastoma (GBM)
[41,42].
Considering that Parkin expression is induced by p53 [43,44] which enhances APE1
ubiquitination [21], it is possible that Parkin ubiquitinates APE1. Moreover, a recent
proteomics study for identifying Parkin’s substrates and interacting proteins revealed APE1
as one of possible targets of Parkin [45]. These observations prompted us to investigate the
activity of Parkin for APE1 ubiquitination. In this study, we investigated functional and
physical interactions between APE1, Parkin, and PINK1.

Materials and Methods
DNA, Cell culture and transient transfection

Author Manuscript
Author Manuscript
Author Manuscript

All cDNAs in plasmid expression vectors used in this study are of humans. Expression
vectors for YFP-Parkin (23955) and cMyc-PINK1 (13314) [46,47] were obtained from
Addgene. Non-tagged wild-type (wt) PINK1 was then cloned by PCR amplification into
pcDNA3.1 (Invitrogen). The full-length human Parkin and its specific E2 ligase UbcH7
were cloned for this study by PCR cloning from quick cDNA clone (Clontech) using
Phusion Taq DNA polymerase (NEB) with appropriate primers synthesized (Integrated DNA
Technology) into the pcDNA3.1Zeo(+) expression vector (Invitrogen). Mutations (R275W
and C431F in Parkin and G309D in PINK1) were introduced by PCR subcloning. The
pBi16, a mammalian expression vector with a flippase recognition target (FRT) site and a
doxycycline (dox) inducible-dual promoter [48], is a generous gift from Dr. Grabczyk. The
human Parkin and PINK1 cDNAs were cloned into pBi16 (named pBi16-PaPi,
Supplemental Fig. S1) for inducing both proteins together with dox. All sequences of DNA
amplified by PCR were confirmed by DNA sequencing (ACGT Inc. and GenScript Inc).
MEFla, a mouse embryonic fibroblast cells, deficient in mouse Ape1 (mApe1) and
expressing hAPE1 was described previously for its extremely low APE1 expression [49].
The MEFla cells were cultured in DMEM High Glucose medium (Hyclone) supplemented
with 10% fetal bovine serum (Gemini Inc.), 1% penicillin/streptomycin, 1% L-glutamine
(Hyclone). SH-SY5Y (a human neuroblastoma) and A549 (a human lung adenocarcinoma)
were purchased from ATCC. The HEK293 derivative T-Rex 293 was purchased from
Invitrogen. The T-Rex 293 cells were transfected with pBi16-PaPi and pOG44 expressing
flippase (Flp). 293/pBI16-PaPi (293-PaPi) stable transfectants were selected with 150 μg/mL
hygromycin. The 293-PaPi cells were plated on 60 mm dishes (1×106/dish). After overnight
incubation, Parkin and PINK1 were induced with 2 μg/mL dox. At the same time, drugs
indicated in the results were added in the culture medium, and together incubated for 16 h.
Cells were then harvested for immunoblot analyses.
For transient transfection, cells were plated on 60 mm dishes at 4×105 - 1×106 and incubated
for overnight. Lipofectamine 2000 (Invitrogen) was used for transfection using OptiMEM-I
(Invitrogen) with the vendors’ manual. PINK1 siRNA was purchased from Applied
Biosystem. Introduction of siRNA was standardized for minimum cytotoxicity as the
following method. Semi-confluent SH-SY5Y cells were suspended in the DMEM medium at
1×107 cells/mL, and mixed with 200 nM siRNA. Cell/siRNA suspensions in 0.1 cm cuvettes
were then electroporated using ECM 830 square wave electroporation system (BTX) at
Mol Carcinog. Author manuscript; available in PMC 2018 February 01.
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920V, 120 μF, 2 pulses at 0.1 sec interval. After 15 min at room temperature, cells were
transferred to 100 mm dishes (Corning) containing DMEM complete media, and incubated
for 72 h. When necessary, 10 μM carbonyl cyanide 3-chlorophenylhydrazone (CCCP) was
added after 48 h, and further incubated for 24 h (total 72 h after the electroporation). Cells
were then harvested and examined with immunoblot.
Immunoblot (Western blot) assay
Whole cell extracts were prepared from cells detached by scraping after being washed with
PBS twice, and resuspended in RIPA buffer [50] supplemented with proteinase inhibitor
cocktail (Roche) and 40 μM MG132. After adjusting protein concentration, the extracts were
run in 10% acrylamide SDS-PAGE, transferred to PVDF membrane (Bio-Rad), and blotted
with appropriate antibodies. SDS-PAGE samples were run with a pre-stained protein size
marker (NEB, P7709).

Author Manuscript

Detection of ubiquitinated APE1 in A549
Histidine hexamer-tagged ubiquitin (6xHis-ub) cDNA was transfected with APE1, Parkin,
and PINK1 in A549 cells and incubated for 24 h. The cells were lysed in the binding buffer
(20 mM Tris pH 8.0, 0.5 M NaCl, 0.1 % NP-40, 10 mM imidazole) with 40 μM MG132
(Sigma) and proteinase inhibitor cocktail without EDTA (Roche). The crude cell extracts
(total fraction) were incubated with Ni-NTA magnetic beads (Qiagen) for 15 min at 4 °C,
washed with the binding buffer, and eluted with binding buffer with 120 mM imidazole. The
total and eluted (His-tagged protein-enriched) fractions were analyzed by immunoblot using
anti-APE1 antibody.
Analysis of localization of YFP-Parkin and APE1

Author Manuscript

MEFla cells were spread on coverslips a day before DNA transfection. The cDNA carrying
YFP-Parkin and APE1 were co-transfected in the same way as described above, and
incubated for 24 h. If necessary, MG132 was added and incubated. Cells were incubated in
the presence of Mitotracker Red (Invitrogen), fixed in 3.7% formaldehyde, and then
permeabilized in PBS containing 0.2% TritonX-100 for 15 min. After washing with PBS
twice, cells were blotted with anti-APE1 antibody, stained with anti-mouse IgG antibody
conjugated to Alexa Fluor 488 (Invitrogen) followed by DAPI staining, and mounted on
glass plates with Vector Lab mounting reagent. Cells were then analyzed with Leica TSP
SP5 Confocal Microscope confocal microscopy at the Imaging Core facility of University of
Kentucky.
Co-immunoprecipitation (co-IP) of recombinant APE1-FLAG and Parkin

Author Manuscript

E. coli BLR(DE3) strain (EMD Biosciences) was transformed with a pRSF-Duet1 derivative
(EMD) carrying Parkin and either of APE1-FLAG or APE1 (negative control) cDNAs. The
cells were grown until OD600 reached 0.6 to 0.8, and then expressions of the proteins were
induced with 0.5 mM IPTG (Fisher) at 16°C for 16 h [20,51]. Cells were lysed in a co-IP
buffer (120 mM NaCl, 2mM EDTA, 0.1mM EGTA, 0.05% NP40, 1 mM DTT, 50mM
HEPES pH 7.9) supplemented with proteinase inhibitor cocktail (Complete Ultra Mini,
Roche). After centrifugation for 20 min at 4°C, small portions of supernatants were kept
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separately as total fractions (inputs), and the remaining samples were subjected to
immunoprecipitation with agarose resin conjugated to the anti-FLAG antibody M2 (Sigma).
The resin was washed in the co-IP buffer, and eluted in 100 μg/mL FLAG peptide (Sigma),
and both total and IP fractions were analyzed by immunoblotting using anti-APE1 and antiParkin antibodies.
Proximity Ligation Assay (PLA)
A549 cells were spread on coverslips and incubated for overnight before transfection of the
APE1 and Parkin cDNA. The cells were then incubated with 1 μM Mitotracker RED for 1 h,
and fixed in 100% methanol at −20°C and then in 100% ice-cold acetone.

Author Manuscript

The samples were processed according to the OLINK Bioscience DuoLink In Situ protocol.
Briefly, the coverslips were rehydrated in PBS (pH7.5) containing 0.1% Triton X-100 (v/v)
for at least 30 minutes at room temperature. The samples were then blocked with 5% BSA in
PBS+ Triton X-100 for 30 minutes. The primary antibodies were applied (1:200 ms-antiparkin, 1:250 rb-anti-APE1) and incubated overnight at 4°C in a humidity chamber; all other
incubations were carried out in a 37°C humidity chamber unless otherwise noted. The
samples were washed and incubated with the Duolink secondary antibodies (anti-mouse and
anti-rabbit IgG) for 1 hour. After washing, the samples were incubated with the ligation
reaction mixture for 30 minutes, washed, and then further incubated with the green
amplification reagent for 90 minutes. After the final wash, the samples were mounted with
Duolink In Situ mounting medium containing DAPI. The fluorescent signals in the cells
were analyzed using an Olympus inverted fluorescence microscope.
Tissue extract preparation

Author Manuscript

Snap-frozen GBM specimens were obtained from male patients (50–75 years old) in
accordance with IRB regulations. Whole cell lysates of the tissues were prepared using the
Fisher Cryo-homogenizing system. Briefly, the samples were disaggregated through
grinding with a clean pre-chilled mortar and pestle. The samples were then transferred to a
micro-centrifuge tube and RIPA buffer, containing 40 μM MG132 and protease inhibitors,
was added to an approximate concentration of 10 mg/μL pre-ground weight. The samples
were then centrifuged to collect large debris, and the supernatant was used to prepare a stock
in SDS-PAGE loading buffer and to determine final protein concentration. The SDS-PAGE
stock was sonicated and incubated at 70° C for 5 min and stored at −80° C until use. Before
SDS-PAGE, the samples were diluted to a final concentration of 3 μg/μL in SDS-PAGE
loading buffer.

Author Manuscript

Immunohistochemistry for GBM and control tissues
A combined total of 17 GBMs and control brain tissues were obtained from the Markey
Cancer Center Biospecimen and Tissue Procurement Shared Resource Facility (BSTP SRF).
Formal-dahydefixed paraffin embedded 5 μm sections were deparaffinized in xylene and
rehydrated stepwise using graded ethanol and finally water. Dako antigen retrieval buffer
was used with a Biocare Medical decloaking chamber for antigen retrieval following the
manufacturer’s protocol. Dako peroxidase blocking reagent was used to inhibit endogenous
peroxidase activity. Sections were incubated with primary antibody for 1 hour at room
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temperature: APE1, Parkin. Next, sections were incubated with polymer linked secondary
antibody, either mouse (Dako K4007) or rabbit (Dako K4003) for 30 min at room
temperature followed by development with diaminobenzodine. Following washing, slides
were counterstained with Meyer’s hematoxylin and allowed to Blue in Ammonia water
before dehydration in graded ethanol. Slides were incubated in xylene before affixing
coverslip.
High-resolution digital image slides of GBM and control brain tissue were obtained by
scanning with the Aperio ScanScope (Leica) at 20x magnification. Aperio ImageScope
software V 11.2.0.780 and the software’s algorithms for Positive Pixel Count V9 and
Nuclear V9 were used to analyze these images for % total intensities for APE1 and Parkin in
tissue and nuclear localization respectively.

Author Manuscript

Chemicals and other reagents
CCCP and MG132 were purchased from Sigma. Antibodies used in this study are those for
APE1 (Santa Cruz, sc-55498), PINK1 (Novus BC100-494 and Protein Tech 23274-1-AP),
Parkin (Santa Cruz, sc-32282), β-tubulin (Santa Cruz, sc58884), GAPDH (Invitrogen,
AM4300), p53 (Santa Cruz, sc-126). Pre-stained protein molecular weight marker was
purchased from New England Biolab (P7709).

Results
Direct involvement of Parkin in APE1 ubiquitination

Author Manuscript

To test whether APE1 is ubiquitinated by Parkin, protein extracts from A549 expressing
histidine hexamer-tagged ubiquitin (His-Ub), APE1, Parkin and PINK1 were subjected to
enrichment of His-Ub through nickel resin purification [21]. Monoubiquitinated as well as
polyubiquitinated APE1 were detected in the His-Ub enriched fraction when Parkin was
expressed (Fig. 1A lane 2 v.s. lane 1). The results indicated Parkin was capable of
ubiquitinating APE1. The His-Ub diminished when PINK1 was co-expressed while intact
APE1 decreased (lane 3 v.s. lane 4), suggesting that PINK1 was required for
polyubiquitination and degradation of APE1.
To understand functional requirements of Parkin and PINK1 for APE1 ubiquitination, a
mouse embryonic fibroblast cell line MEFla (MEFlowAPE1) [49] was transiently transfected
with Parkin, PINK1, and APE1. APE1 levels were not altered when either Parkin or PINK1
was expressed alone (Fig. 1B lanes 3 and 4 v.s. lane 2). However, expressing both Parkin and
PINK1 caused a marked APE1 decrease (Fig. 1B lane 5; also in Fig. 1D lane 3, Fig. 1E lane
3E, and Fig. 1F lane 2).

Author Manuscript

p53 is a well known target of ubiquitination by other E3 ubiquitin ligases [52–54]. We tested
whether p53 was also efficiently ubiquitinated by Parkin. However, the stability of p53 was
unaffected by Parkin and PINK1 (Fig. 1C). Similarly, proliferating cell nuclear antigen
(PCNA), highly susceptible to mono- and poly-ubiquitination [54], was not modified by
Parkin (Fig. 1C). The unaltered stabilities of p53 and PCNA as well as β-tubulin and β-actin
indicated a high specificity of the reaction of Parkin on APE1. Incubating cells with a 26S
proteasome inhibitor MG132 restored the APE1 level (Fig. 1D, lane 4 v.s. lane 3).
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The Parkin polypeptide contains two RING domains (Fig. S2). R275W and C431F missense
mutations, which are located in the first and second RING domains in Parkin respectively
(Fig. S2), abrogate its E3 ligase activity and cause early onset PD [39,55]. These Parkin
mutants failed to degrade APE1 (Fig. 1D lanes 5 and 9; Table 1). PINK1 carrying G309D
missense mutation is defective in its kinase activity (Fig. S2), and incapable of activating
Parkin [47,56,57]. The G309D PINK1 did not activate APE1 degradation (Fig. 1D lane 6;
Table 1). These results suggested that the ligase activity of Parkin was required for APE1
degradation, for which the kinase activity of PINK1 was also critical.
Interaction of APE1 with Parkin

Author Manuscript

Sarraf et al. recently identified proteins interacting with Parkin and their possible
ubiquitination sites, and APE1 was found to be a protein interacting with Parkin through its
N-terminal segment, i.e., 20–30th amino acids from N-terminus [45]. To probe the
importance of the N-terminal region of APE1 for the stability, MEFla cells were transiently
transfected with N-terminally truncated APE1, ND20 and ND41 (N-terminal 20 and 41
amino acids deletions), along with Parkin and PINK1. While ND20 APE1 was efficiently
degraded by Parkin (Fig. 1E and Table 1), ND41 APE1 was significantly more resistant to
Parkin dependent degradation compared to those of the full-length and ND20 APE1 (Fig. 1F
and Table 1). It is likely that APE1 is mainly ubiquitinated at the amino acid residues 20–41
which contains two Lys clusters (24K-25K-27K and 31K-32K-35K), which is consistent
with the previous studies showing that the N-terminal residues contained major ubiquitin
acceptor Lys residues catalyzed by MDM2 and UBR3 [21,24].

Author Manuscript
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In the normal condition, APE1 in MEFla was localized predominantly in the nuclei (Fig. 2A,
control). When the cells were treated with MG132, cytoplasmic APE1 was visibly increased
3 h after the treatment, and became indistinguishable from the nuclear APE1 after overnight
incubation of the cells with MG132 (Fig. 2A). The major fraction of Parkin is present in the
cytoplasm [40]. The possibility of cytosolic co-localization of APE1 with Parkin was
elucidated, using YFP-Parkin and APE1. After MG132 treatment, APE1 was found to be colocalized with YFP-Parkin in the cytoplasm (Fig. 2B and Fig. S3). The cytoplasmic colocalization of APE1 and YFP-Parkin suggested that the physical interaction occurred in the
cytoplasm. This possibility was examined with proximity ligation assay (PLA) [58].
Antibodies specific to APE1 and Parkin were used to label the two proteins and signals were
detected when the two proteins were in the proximate location to each other (Fig. 2C). The
PLA signal was detected when APE1 and Parkin were co-expressed. Importantly, the PLA
was observed mainly in the cytoplasm but not in the nuclei or inside of mitochondria. The
absence of Parkin-APE1 interaction in the nuclei is consistent with the cytosolic localization
of Parkin in previous studies [59–61]. To test whether APE1 directly interacts with Parkin
without involvement of other cellular factors such as ubiquitin or PINK1, recombinant
Parkin was expressed with APE1 or with FLAG-APE1 simultaneously in E. coli, and
performed FLAG-immunoprecipitation to detect Parkin in the FLAG-APE1 enriched
fraction. Parkin was specifically detected in the FLAG-APE1 containing fraction (Fig. 2D).
The result indicated that APE1 directly interacts with Parkin. Co-immunoprecipitation of
Parkin by ND41 APE1-FLAG was significantly decreased (Fig. S4) compared to that by
full-length APE1, indicating that the N-terminal segment is pivotal for the interaction.
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However, it should be noted that Parkin signal was not completely disappeared in the ND41FLAG IP fraction, and we could not exclude the possibility that the downstream APE1
polypeptide is also involved in the interaction of APE1 with Parkin.
Ubiquitination and degradation of endogenous APE1 by Parkin and PINK1
To examine the effect of Parkin expression on endogenous APE1, a lung adenocarcinoma
cell line A549 was transiently co-transfected with Parkin and its cofactors [39] [62–65],
namely, Uba1 (E1 ligase), UbcH7 (Parkin-specific E2 ligase), and PINK1 (Fig. 3A). The
level of endogenous APE1 decreased in a does-dependent manner (Fig. 3B). Densitometry
of the immunoblot revealed that the level of the endogenous APE1 was down to 60% of the
control cells transfected with the vector plasmid DNA alone.

Author Manuscript

Levels of the endogenous p53 and PCNA as well as housekeeping proteins β-tubulin and
GAPDH were unaltered by the expression of Parkin and its cofactors (Fig. 3B). These
results indicated a high specificity of the reaction of Parkin on APE1, consistent with the
results with the ectopically expressed proteins (Fig. 1C). Total protein extracts from A549
were analyzed for ubiquitination of endogenous APE1. A specific band appeared at the
position for monoubiquitinated APE1 after cells were transiently transfected with Parkin
(Fig. 3C). Therefore, endogenous APE1 was ubiquitinated and degraded by Parkin.

Author Manuscript

Inducible expression of Parkin and PINK1 without transient transfection would provide a
more refined experimental condition. To achieve this, a derivative of HEK 293 cell line 293PaPi was used. The 293-PaPi is a stable transfectant of HEK293, and enables simultaneous
induction of Parkin and PINK1 by doxycycline from a bidirectional promoter [48] (Fig. S1).
Induction of Parkin and PINK1 (Fig. 4A) did not alter APE1 nor β-tubulin while Mfn2
decreased clearly (Fig. 4B). Because Parkin’s E3 ligase function is active at mitochondria,
the 293-PaPi cells were treated with H2O2 to increase APE1 in mitochondria [66]. Treatment
of the cells with H2O2 decreased APE1 to approximately 70% of the control while the
amount of β-tubulin was still unchanged (Fig. 4B). Although the change of APE1 level by
H2O2 in the dox-treated 293-PaPi was statistically significant, dox or H2O2 alone did not
show significant difference from the untreated control cells (Fig. 4B). These results
indicated that degradation of APE1 by Parkin was limited compared to the transiently
expressed APE1, suggesting that a large portion of APE1 is not in contact with the Parkin
and PINK1 without induction of stresses such as oxidative stress.

Author Manuscript

A human neuroblastoma cell line SH-SY5Y has been used for mitophagy studies because of
a relatively high level of endogenous Parkin in the cells. SH-SY5Y cells were incubated
with CCCP and the APE1 stability was examined. CCCP is a proton ionophore uncoupling
oxidative phosphorylation in mitochondria [67] and stimulates mitophagy via Parkin-driven
degradation of mitochondrial proteins 24 h after CCCP treatment [40]. Mitofusin 2 (Mfn2),
a mitochondria fusion protein and a known Parkin substrate, was decreased after the CCCP
treatment (Fig. 4C). The CCCP treatment also decreased the Parkin level, consistent with
previous observations that Parkin polyubiquitinates itself for degradation as an autofeedback regulation [68,69]. Under this condition, moderate decrease of APE1 was observed
whereas the level of β-tubulin was unchanged. After normalization with β-tubulin, it was
calculated, with statistical significance, that APE1 decreased to 80% of that of untreated
Mol Carcinog. Author manuscript; available in PMC 2018 February 01.
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cells (Fig. 4C). The differentiation status of the SH-SY5Y [70] cells did not affect the Parkin
activity, as cells that were differentiated with retinoic acid also showed a similar level of
decrease of endogenous APE1 with CCCP (Fig. 4C). PINK1 down-regulation by RNA
interference resulted in the stabilization of APE1 (Fig. 4D). These results suggested that
Parkin and PINK1 played a role in regulating APE1 levels in the cells.
Loss of Parkin is associated with elevated APE1 levels in GBM
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Parkin deficiency has been associated with GBM [41,42]. To elucidate the correlation
between Parkin and APE1 in brain tumors, expression levels of Parkin and APE1 in both
GBM and non-neoplastic brain tissues were examined. Qualities of the monoclonal
antibodies for Parkin and APE1 were confirmed in Western blot to detect the corresponding
proteins specifically (Fig. 5A). Interestingly, the GBM tissues showed increased APE1 levels
while decreasing the Parkin levels (Fig. 5A). Parkin and APE1 levels were examined in
detail by immunohistochemistry (Fig. 5B). Parkin levels in the non-neoplastic brain tissues
were higher than those of GBM tissues (Fig. 5C, p = 0.0009), while APE1 signals were
higher in GBM tissues than the non-neoplastic tissues (p = 0.0025). Parkin/APE1 ratios were
calculated, and were significantly lower in the GBM tissues than in the non-neoplastic brain
tissues (Fig. 5C, p = 0.0013). Notably, the variance of Parkin/APE1 ratios were significantly
lower than that of either APE1 and Parkin levels, implying that the loss of Parkin and the
gain of APE1 expression during the tumorigenesis are associated with each other.

Discussion

Author Manuscript

APE1 is primarily known for repair of oxidized and alkylated DNA damage, but also is an
important gene expression regulator that activates transcription factors such as AP-1 and
NFκB [71]. Both APE1 functions are pro-proliferation and advantageous to cell survival,
which explains elevated APE1 expression in tumor tissues. Indeed, tumor cells with high
APE1 levels acquire drug and radiation resistance [8–12]. Therefore, identifying factors that
control APE1 levels should provide information relevant to the cancer therapeutics,
particularly those causing cyto-toxicity via DNA damage generation.

Author Manuscript

We speculated a possible role of Parkin for controlling intracellular levels of APE1, because
(1) backup E3 ligase activity was detected in cells defective in MDM2 [20], (2) Parkin is
induced by p53 [43,44], and (3) a proteomics study detected APE1 as a possible substrate of
Parkin [45]. The present results show that Parkin is a quite efficient and highly specific E3
ligase to ubiquitinate APE1. The examination of mutant Parkin and PINK1 supports that the
ubiquitination reaction is dependent on the E3 ligase activity of Parkin and the kinase
activity of PINK1. Evidence for the direct interaction of APE1 with Parkin was obtained
with co-immunoprecipitation of APE1 and Parkin and by proximity ligation assay. Based on
these results, we conclude that Parkin directly ubiquitinates APE1. While monoubiquitinated
APE1 was readily detected by MDM2 and UBR3 [21,24], detection of monoubiquitinated
APE1 catalyzed by Parkin and PINK1 was relatively difficult. This observation implies that
monoubiquitinated APE1 immediately undergoes polyubiquitination process by Parkin, and
APE1 is efficiently degraded after the reaction by Parkin. Inhibiting the 26S proteasome by
MG132 resulted in increase of monoubiquitinated APE1 in a manner dependent on Parkin
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and PINK1. Thus, Parkin with its cofactors Uba1, UbcH7, and PINK1 ubiquitinates directly,
and degrades APE1 through 26S proteasome more efficiently than those processed by
MDM2 and UBR3.
While ND20 APE1 (N-terminal 20 a.a. truncation) was degraded by Parkin as effectively as
the full-length APE1, the stability of ND41 APE1 in the presence of Parkin and PINK1 was
significantly increased. The results indicated that the N-terminal polypeptide between 20 to
40 amino residues in APE1 is important for the Parkin-dependent ubiquitination.
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The N-terminal 60 amino acid segment in APE1 is not defined well functionally and
structurally. This domain is unique in the mammalian AP endonuclease [72], and is
dispensable for the AP-endonuclease activity [73], and thus it has been speculated that the
N-terminal domain has an uncharacterized function unique to mammalian cells. In this
context, it is interesting that the segment is rich in Lys, the major acceptor for acetylation
and ubiquitination. The N-terminal segment between 20 and 41 amino acid residues contains
six Lys residues, namely, 24K, 25K, 27K, 31K, 32K, and 35K. Acetylation of APE1 at these
Lys residues were reported [7,14,18,74]. These N-terminal Lys residues were also the main
ubiquitin acceptors for MDM2 and UBR3 E3 ligases [21,24]. Based on a recent quantitative
proteomics study, the APE1 segment 18-RTEPEAKKSKTAA-30, containing Lys 24, 25 and
27, was identified to be a possible target of ubiquitination catalyzed by Parkin [45].
Therefore, Lys residues in the N-terminus may be essential for the post-translational
modifications that modulates APE1’s gene regulatory function [7] and for altering its
stability by polyubiquitination.
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Although activating Parkin resulted in decrease of endogenous APE1 in three cell lines, SHSY5Y, A549, and 293-PaPi, it should be noted that Parkin was active on endogenous APE1
only when stressful conditions (CCCP and H2O2) were invoked. We speculate that the
modest effect of Parkin on endogenous APE1 is due to the fact that the majority of
endogenous APE1 is compartmentalized in the nuclei, which may prevent Parkin from
reacting on APE1. Stresses induced in the cells activated Parkin system (CCCP in SHSY5Y) or facilitated mitochondrial localization of APE1 from nuclei (H2O2 in 293) [66].
Although endogenous APE1 significantly decreased in A549 without any treatments,
transient transfection is known to induce stress responses [75,76]. Thus, APE1
ubiquitination by Parkin is unique in that the main site of the reaction is the cytoplasm,
which is supported by the proximity ligation assay. In contrast, APE1 ubiquitination by
MDM2 and UBR3 occurred mainly in the nuclei [20,24]. It should be noted that APE1 was
co-purified with mitochondria, but majority of this APE1 fraction was found to be on the
surface of mitochondria [77], which is the major platform for the Parkin driven protein
degradation. However, it is highly plausible in the event of mitophagy, APE1 in the
mitochondria becomes the target of Parkin as well.
While APE1 has been studied for its activities in the nuclei, there is an increasing interest in
APE1’s presence in the cytoplasm and its cancer-promoting effect [78–80]. Kakolyris et al.
found that APE1 was present in the cytoplasm of the normal human tissues [81]. More
recently, malignant cancer cells in the lung exhibited cytoplasmic APE1 at unusually high
levels, and was linked to a poor prognosis of cancer treatment [79]. Vascott et al. found that

Mol Carcinog. Author manuscript; available in PMC 2018 February 01.

Scott et al.

Page 11

Author Manuscript

treatment of cells with an APE1 inhibitor E3330 caused cytoplasmic translocation of APE1
[82]. Frossi also found that H2O2 induced translocation of APE1 into mitochondria [66].
These studies suggest a cellular mechanism to export APE1 from nuclei. Based on these
previous studies and present results, it is postulated that APE1 ubiquitination by Parkin is
active in the cytoplasm, in which damaged APE1 proteins are ubiquitinated and degraded by
Parkin to protect cells from undergoing malignant transformation. Meanwhile, undamaged,
properly folded APE1 in the nucleus may be protected from this salvage system by the
compartmentalization.
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Originally identified as a gene of which deficiency is responsible for PD, Parkin was
recently reported as a tumor suppressor gene of which loss of heterozygosity was frequently
found in GBM [41]. Analysis of Parkin and APE1 expressions in normal and GBM
specimens revealed that Parkin/APE1 ratios (expression of Parkin relative to that of APE1)
in the GBM tissues were uniformly low, while those in the non-neoplastic brain tissues
showed much higher values and larger variance than those in GBM. This observation
implies a correlation between the loss of Parkin and the high expression of APE1 in the
brain tumor tissues. It is possible that a lack of Parkin activity either by loss of
heterozygosity or by p53 mutation may lead to deficiency in regular APE1 degradation, and
may accumulate in the cytoplasm as well as in the nuclei. However, the results do not
determine whether Parkin deficiency is the direct cause of high APE1 activities in GBM, or
vice versa. More recently, Hu et al. reported that melanoma specific inactivation of the
Parkin gene [83]. According to the study, melanoma specific Parkin alterations were
observed at significantly high odds ratios over healthy control tissues The alterations
included copy number variations, splicing mutations, and putatively inactivating mutations
including N273S, R275W, and P437L which are adjacent to the missense mutations that
cause early onset Parkinson’s disease (R275W and C431F). Further studies are necessary to
investigate whether Parkin is crucial for the tight regulation of the intracellular level and
subcellular distribution of APE1 to prevent cells from becoming malignant tumors.
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Abbreviations
AP-site

apurinic/apyrimidinic site

APE1

AP-endonuclease 1

CCCP

Carbonyl cyanide 3-chlorophenylhydrazone

co-IP

co-immunoprecipitation
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dox

doxycycline

GBM

glioblastoma multiform

His-Ub

histidine hexamer-tagged ubiquitin

MDM2

mouse double minute 2

MEF

mouse embryonic fibroblast

PCNA

proliferating cell nuclear antigen

PINK1

PTEN induced kinase 1

PLA

proximity ligation assay

PTM

post-translational modification

wt

wild-type

YFP

yellow fluorescence protein
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Fig. 1. Functional requirements for APE1 ubiquitination
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(A) Detection of monoubiquitinated and polyubiquitinated APE1. A549 was transfected
with APE1 and His-tagged Ubiquitin (His-Ub) along with vector control (lane 1), Parkin
(lanes 2 and 3), Parkin and PINK1 (lane 4). Total protein lysates and eluted fractions
(enriched with His-Ub) were analyzed with APE1 antibody as described in Materials and
Methods. (B) MEFla transfected with 1: vector control, 2: APE1, 3: APE1 and Parkin, 4:
APE1 and PINK1, 5: APE1, PINK1, and PARKIN, 6: APE1, PINK1, PARKIN with 10 μM
MG132 for 6 h. (C) MEFla transfected with APE1, PCNA, p53 without (ctrl) or with Parkin
and PINK1 (PaPi) and the stabilities of APE1, PCNA, p53 were monitored after 24 h. (D)
Wild-type (WT) or mutant Parkin (275 = R275W, 431 = C431F) and PINK1 (309 = G309D)
were co-transfected in MEFla as shown in the table. Protein levels were examined after 24 h
incubation. MG132 was at 3 μM for 16 h. (E) The WT (full-length) or ND20 (N-terminal 20
a.a. truncation) APE1 was co-transfected with Parkin and PINK1 in MEFla. Lane 6: MG132
was added at 3 μM for overnight incubation. Expression of PINK1 in lanes 3 and 5 was
confirmed separately from lane 6 which otherwise caused a halo effect. (F) ND41 (41 a.a.
N-terminal truncation) APE1 was examined after Parkin and PINK1 expression.
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Fig. 2. Interaction of APE1 with Parkin in the cytoplasm
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(A) Accumulation of APE1 in the presence of MG132. MEFla cells expressing the wild-type
APE1 were incubated with MG132 for indicated time periods. MG132 concentrations were
40 μM (0 – 3 h) and 3 μM (overnight). APE1 was labeled with anti-APE1 antibody and
AlexaFluor 488 and analyzed in fluorescence microscopy. (B) MEFla transfected with APE1
and YFP-Parkin were incubated with MG132 40 μM for 3 h, fixed, labeled with anti-APE1
and AlexaFluor 633 (shown in purple), and then analyzed by confocal microscopy. Red:
MitoTracker Red, Green: YFP-Parkin, Blue: APE1, X: Merged. Z-series pictures were taken
for a detailed analysis (Fig. S3). (C) Proximity ligation assay (PLA) between APE1 and
Parkin in A549. A549 expressing APE1, Parkin, PINK1 as indicated. APE1 and Parkin
specific antibodies were used to probe the interactions of the two proteins as described in
Materials and Methods. Positive signals were seen only in the cells co-transfected with
APE1, Parkin, PINK1 (bottom panel shown with arrows). MT: fluorescent signals by
MitoTracker Red (Invitrogen). (D) Co-immunoprecipitation of APE1 and Parkin. Parkin and
APE1 (lane 1) or Parkin and APE1-FLAG (lane 2) co-expressed in E. coli BLR were
subjected to immunoprecipitation using FLAG antibody, and the total and eluted fractions
were analyzed in immunoblot using APE1 and Parkin antibodies.
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Fig. 3. Parkin targets endogenous APE1 for degradation
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(A) Expression of Parkin and its cofactors, Uba1, UbcH7, Parkin and PINK1 in A549. A549
was transfected with (−) empty vector alone or (+) the vectors carrying Parkin, PINK1,
Uba1, and UbcH7 cDNAs. β-tub: β-tubulin. Note that there was no change in the Uba1
probably due to its abundance. (B) A549 cells were transfected with cDNA expression
vectors for ubiquitin, UBA1, UBCH7, Parkin, PINK1. Amount of each DNA: 1: 0 μg, 2:
0.17 μg, 3: 0.35 μg, 4: 0.7 μg. Empty vector DNA (vec) was added to each to make the total
amount of DNA equal among samples. Cells were then incubated for 16 h, and harvested for
immunoblot examination. (C) A549 transfected with vector alone (1) or ubiquitin, Uba1,
UbcH7, Parkin and PINK1 as in (B) and incubated with MG132 (3 μM for 16 h), and APE1
(middle) and its ubiquitinated forms (top), as well as β-tubulin (bottom) were analyzed by
immunoblot separately.
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Fig. 4. Effect of Parkin and PINK1 co-expression on endogenous APE1
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(A) Parkin and PINK1 expressions examined in 293-PaPi cell lysates after 16 h treatment
without (lane 1) or with (lane 2) dox (2 μg/mL). (B) (Left) Immunoblot for APE1, Parkin,
Mfn2, and β-tubulin levels in 293-PaPi cells treated with dox for 16 h. CCCP: 10 μM; H2O2:
50 μM. (Right) Averages of APE1/β-tubulin ratios with the treatments as indicated. *p <
0.05. (C) SH-SY5Y cells were incubated with DMSO only (−) or with 10 μM CCCP (+),
and incubated for 24 h at 37°C and analyzed by immunoblot. In the right panel, SH-SY5Y
cells were differentiated by the 5-days treatment with 10 μM retinoic acid (RA), and then
incubated with 10 μM CCCP for 24 h. (D) Scrambled control (lanes 1 and 2) or PINK1
siRNA (lane 3) were electroporated in SH-SY5Y, and the level of APE1 was examined after
72 h incubation with 24 h treatment of DMSO (lanes 1 and 3) or 10 μM CCCP (lane 2).
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Fig. 5. Parkin and APE1 expressions in GBM
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(A) Five glioma and one non-neoplasic (from epilepsy surgery) brain tissues were processed
for protein extraction and analyzed in immunoblot assays. (B) Representative results of
immunohistochemistry from non-neoplastic (Control) and GBM tissues. Magnifications: 1x,
5x, and 20x. (C) Total levels of APE1 (Left panel) and Parkin (Middle panel) were
measured and normalized by nuclear counts using Aperio analytical software (Leica), and
are shown as box plots for the non-neoplastic (N) and GBM brain tissues. (Right panel)
Parkin levels were divided by APE1 levels of the corresponding tissues, and the calculated
ratios are plotted. Each box plot shows the median value (bold horizontal line), the first and
third quartile (box), and 1.5 x interquartile range (whiskers). Individual values are also
shown as circles. The p values (Student’s t-test) are 0.009, 0.0025, 0.0013 for the left,
middle, and the right panel, respectively.
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Effect of Parkin and PINK1 on the stability of APE1a.
APE1

Parkin

PINK1

Decrease (%)b

pc

WT

WT

WT

46.0 ± 18.0

-

ND21

WT

WT

42.9 ± 7.5

0.63

ND41

WT

WT

83.4 ± 24.4

0.008

WT

R275W

WT

81.7 ± 5.90

< 0.001

WT

C431F

WT

109.0 ± 12.03

< 0.001

WT

WT

G309D

96.17 ± 31.0

< 0.001

WT

WT

-

97.3

WT

-

WT

84
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a

Relative APE1 intensities (%) in MEFla with the wild-type or mutant Parkin and PINK1 expressions were calculated by comparing with those
without Parkin nor PINK1.

b

APE1 amounts were normalized by β-tubulin, and compared with that without Parkin and PINK1. Values based on more than three independent
experiments.

c
P values by Student’s t-test. Each value (more than three experiments) calculated with the result of the first row (with wt-APE1, wt-Parkin, and
wt-PINK1).
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